Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

Chromocell Corporation

Achelios Therapeutics is a company focused on developing therapeutics for pain management and related conditions.

Achelios Therapeutics

AnaBios is a biotechnology company specializing in human tissue-based platforms for drug discovery and development.

AnaBios

GW Pharmaceuticals is a global biopharmaceutical company known for developing cannabinoid-based medicines.

GW Pharmaceuticals

Illumina is a leading company in the field of genomics and genetic analysis, providing sequencing and array-based solutions for genetic research.

Illumina

Enterin is a biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, particularly Parkinson's disease.

Enterin

Enzyvant Sciences is a biotechnology company dedicated to developing and commercializing innovative therapies for rare diseases.

Enzyvant Sciences

Chromocell is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Their clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. They aim to develop a novel and proprietary class of NaV blockers that target the body’s peripheral nervous system, initially for Erythromelalgia (“EM”), a rare condition that primarily affects the feet and hands.

Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Chromocell Therapeutics Corporation

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 22, 2024 12:52 AM	28622fe0
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 22, 2024 12:52 AM	379f2e9e
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 22, 2024 12:52 AM	44532f49
translate crunchbase fundingrounds	general
peers	general
news basic	general	Feb 22, 2024 12:52 AM	bbaa585b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CHROMOCELL

Chromocell

Last Close

0.62

21/11 17:33

Market Cap

3.73M

Beta: -

Volume Today

44.80K

Avg: -